We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

84 hedge funds and large institutions have $184M invested in Kalaris Therapeutics in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 26

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0.12% more ownership

Funds ownership: 1.7% → 1.81% (+0.12%)

0% more funds holding

Funds holding: 84 → 84 (0)

44% less capital invested

Capital invested by funds: $329M → $184M (-$145M)

Holders
84
Holders Change
–
Holders Change %
0%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
28
Reduced
26
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$12.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.82M
3
GC
GMT Capital
Georgia
+$4.04M
4
JP Morgan Chase
JP Morgan Chase
New York
+$1.44M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$1.1M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$5.62M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$3.38M
3
EOJOAM
E. Ohman J:or Asset Management
Sweden
-$1.18M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1,000K
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$816K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$53.6M +$4.82M +24,151 +8%
Vanguard Group
2
Vanguard Group
Pennsylvania
$18.1M -$1,000K -5,012 -4%
AG
3
Artal Group
Luxembourg
$15.7M – – –
BlackRock
4
BlackRock
New York
$15.1M +$544K +2,728 +3%
RCM
5
RA Capital Management
Massachusetts
$9.72M +$12.5M +62,632 New
AIG
6
American International Group
New York
$7.72M -$8.98K -45 -0.1%
GC
7
GMT Capital
Georgia
$7.68M +$4.04M +20,274 +69%
WP
8
Woodline Partners
California
$7.34M – – –
RG
9
Redmile Group
California
$5.56M – – –
Massachusetts Financial Services
10
Massachusetts Financial Services
Massachusetts
$5.3M +$188K +943 +3%
JP Morgan Chase
11
JP Morgan Chase
New York
$5.16M +$1.44M +7,204 +28%
Alkeon Capital Management
12
Alkeon Capital Management
New York
$5.09M -$105K -526 -2%
State Street
13
State Street
Massachusetts
$3.88M -$5.62M -28,170 -53%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$3.71M +$103K +516 +2%
Marshall Wace
15
Marshall Wace
United Kingdom
$2.19M -$26.1K -131 -0.9%
Northern Trust
16
Northern Trust
Illinois
$1.92M -$118K -590 -5%
Charles Schwab
17
Charles Schwab
California
$1.39M -$28.7K -144 -2%
Millennium Management
18
Millennium Management
New York
$965K +$637K +3,191 +105%
Federated Hermes
19
Federated Hermes
Pennsylvania
$860K +$1.1M +5,538 New
Two Sigma Investments
20
Two Sigma Investments
New York
$782K +$237K +1,190 +31%
Citadel Advisors
21
Citadel Advisors
Florida
$736K +$424K +2,123 +81%
Goldman Sachs
22
Goldman Sachs
New York
$730K +$134K +674 +17%
State of Wisconsin Investment Board
23
State of Wisconsin Investment Board
Wisconsin
$633K +$594K +2,978 +271%
GCP
24
GSA Capital Partners
United Kingdom
$629K -$143K -715 -15%
Morgan Stanley
25
Morgan Stanley
New York
$622K +$376K +1,884 +89%
1
2 3 4

KLRS Hedge Fund Activity: Q1 2022 in Review

84 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2022, worth a combined $184M — down 44% from $329M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KLRS positions and 14 closed out — a net gain of 1 holder — while 28 added to existing stakes and 26 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $12.5M. The largest seller was State Street, cutting an estimated $5.62M.

  • 84 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $184M of Kalaris Therapeutics stock for Q1 2022, down 44% quarter-over-quarter.
  • 15 funds opened new Kalaris Therapeutics positions in Q1 2022 and 14 closed out, a net change of +1 holder.
  • The largest Kalaris Therapeutics buyer in Q1 2022 was RA Capital Management, an estimated $12.5M added.
  • The largest Kalaris Therapeutics seller in Q1 2022 was State Street, an estimated $5.62M sold.

Based on aggregated 13F filings for Q1 2022.